Azalea Therapeutics
Bedford, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $82M
Overview
Developing next-generation biologic drugs for major retinal diseases such as AMD and diabetic retinopathy.
Ophthalmology
Technology Platform
A protein engineering platform focused on designing and optimizing biologic therapeutics for intraocular delivery and sustained action.
Funding History
1Total raised:$82M
Seed$82M
Opportunities
Large, established market with a clear need for therapies that reduce treatment burden and improve outcomes.
Risk Factors
High clinical and regulatory bar to displace standard-of-care biologics, and significant commercial competition.
Competitive Landscape
Competes in a crowded anti-VEGF market and must differentiate from entrenched standards of care and numerous other novel biologic approaches.